Efficacy and safety of daclizumab beta in patients with relapsing-remitting multiple sclerosis switching from natalizumab: rationale and study design of the phase 3b SUSTAIN study

Authors

• Stanley Cohan, Providence Multiple Sclerosis Center, USA.Follow

Document Type

Article

Publication Date

2018

Keywords

oregon; providence neuroscience institute

Area of Special Interest

Neurosciences (Brain & Spine)

Specialty/Research Institute

Neurosciences